456
Views
22
CrossRef citations to date
0
Altmetric
Research Article

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia

, , , , , , , , , , , , , , , , , & show all
Pages 1028-1035 | Received 23 Jun 2012, Accepted 27 Sep 2012, Published online: 06 Nov 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Jonathan A. Webster & Keith W. Pratz. (2018) Acute myeloid leukemia in the elderly: therapeutic options and choice. Leukemia & Lymphoma 59:2, pages 274-287.
Read now
Caroline Bret, Elena Viziteu, Alboukadel Kassambara & Jerome Moreaux. (2016) Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. Expert Review of Hematology 9:4, pages 351-360.
Read now
Magdalena Koszarska, Nora Meggyesi, Andras Bors, Arpad Batai, Otto Csacsovszki, Eniko Lehoczky, Emma Adam, Andras Kozma, Nora Lovas, Andrea Sipos, Tunde Krahling, Janos Dolgos, Peter Remenyi, Sandor Fekete, Tamas Masszi, Attila Tordai & Hajnalka Andrikovics. (2014) Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. Leukemia & Lymphoma 55:7, pages 1510-1517.
Read now

Articles from other publishers (19)

Yao Qin, Kai Shen, Ting Liu & Hongbing Ma. (2023) Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis. BMC Cancer 23:1.
Crossref
Petra Kövy, Zoltán Őrfi, András Bors, András Kozma, László Gopcsa, János Dolgos, Nóra Lovas, József Harasztdombi, Viktor Lakatos, Ágnes Király, Gábor Mikala, István Vályi-Nagy, Péter Reményi & Hajnalka Andrikovics. (2021) Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLOS ONE 16:6, pages e0253386.
Crossref
Amy Burd, Ross L. Levine, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Prapti Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary Schiller, Rebecca Olin, Mark Litzow, James Foran, Tara L. Lin, Brian Ball, Michael Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha Arellano, Alison Walker, Vu. H. Duong, Tibor Kovacsovics, Robert Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Jo-Anne Vergilio, Tim Brennan, Christine Vietz, Eric Severson, Molly Miller, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Timothy Chen, Mona Stefanos, Brian Druker & John C. Byrd. (2020) Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature Medicine 26:12, pages 1852-1858.
Crossref
Helen Winter, Pamela J. Kaisaki, Joe Harvey, Edoardo Giacopuzzi, Matteo P. Ferla, Melissa M. Pentony, Samantha J.L. Knight, Ricky A. Sharma, Jenny C. Taylor & James S.O. McCullagh. (2019) Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma. Cancers 11:12, pages 1895.
Crossref
Raffaella Accetta, Leonardo Campiotti, Lorenzo Elli, Rosario Casalone & Francesco Pallotti. (2018) A particular case of AML patient with the polymorphism G105G (rs11554137) and the missense mutation R132C in IDH1 gene . Clinical Chemistry and Laboratory Medicine (CCLM) 57:2, pages e30-e33.
Crossref
Paolo Gallipoli & Brian J.P. Huntly. (2018) Novel epigenetic therapies in hematological malignancies: Current status and beyond. Seminars in Cancer Biology 51, pages 198-210.
Crossref
Hamoud Al-Khallaf. (2017) Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell & Bioscience 7:1.
Crossref
Qingyu Xu, Yan Li, Na Lv, Yu Jing, Yihan Xu, Yuyan Li, Wenjun Li, Zilong Yao, Xiaosu Chen, Sai Huang, Lili Wang, Yonghui Li & Li Yu. (2017) Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Clinical Cancer Research 23:15, pages 4511-4522.
Crossref
Diego Avellaneda Matteo, Adam J. Grunseth, Eric R. Gonzalez, Stacy L. Anselmo, Madison A. Kennedy, Precious Moman, David A. Scott, An Hoang & Christal D. Sohl. (2017) Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency. Journal of Biological Chemistry 292:19, pages 7971-7983.
Crossref
Dalia Salem, Sherin Abd El-Aziz, Nadia El-Menshawy, Tarek Abouzeid & Mohamed Ebrahim. (2016) Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype. Indian Journal of Hematology and Blood Transfusion 33:1, pages 49-55.
Crossref
Jing-Yi Chen, You-Syuan Lai, Hui-Jen Tsai, Cheng-Chin Kuo, B. Linju Yen, Su-Peng Yeh, H. Sunny Sun & Wen-Chun Hung. (2016) The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. Scientific Reports 6:1.
Crossref
Anna Eriksson, Andreas Lennartsson & Sören Lehmann. (2015) Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. Experimental Hematology 43:8, pages 609-624.
Crossref
Amir T. Fathi, Seth A. Wander, Rawan Faramand & Ashkan Emadi. (2015) Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Seminars in Hematology 52:3, pages 165-171.
Crossref
Paolo Gallipoli, George Giotopoulos & Brian J.P. Huntly. (2015) Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Therapeutic Advances in Hematology 6:3, pages 103-119.
Crossref
Rimma Berenstein, Igor Wolfgang Blau, Asiye Kar, Ruhiye Cay, Annette Sindram, Claudia Seide & Olga Blau. (2014) Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia. Journal of Experimental & Clinical Cancer Research 33:1.
Crossref
A P Im, A R Sehgal, M P Carroll, B D Smith, A Tefferi, D E Johnson & M Boyiadzis. (2014) DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 28:9, pages 1774-1783.
Crossref
Anna Sophia McKenney & Ross L. Levine. (2013) Isocitrate dehydrogenase mutations in leukemia. Journal of Clinical Investigation 123:9, pages 3672-3677.
Crossref
Craig Horbinski. (2013) What do we know about IDH1/2 mutations so far, and how do we use it?. Acta Neuropathologica 125:5, pages 621-636.
Crossref
Julie-Aurore Losman & William G. KaelinJr.Jr.. (2013) What a difference a hydroxyl makes: mutant IDH, ( R )-2-hydroxyglutarate, and cancer . Genes & Development 27:8, pages 836-852.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.